You are here

SABCS

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

Fierce Pharma

Fri, 12/9/22 - 10:54 am

SABCS: Novartis touts Kisqali's 5-year breast cancer survival, advantage over Pfizer's Ibrance

Fierce Pharma

Wed, 12/9/20 - 10:51 am

Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer

Pharmaceutical Business Review

Fri, 12/13/19 - 12:20 pm

HER2+ breast cancer

SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short

Fierce Pharma

Thu, 12/12/19 - 11:12 am

immuno-oncology

triple-negative breast cancer

SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis

Fierce Pharma

Wed, 12/11/19 - 10:35 am

SABCS: Seattle Genetics hails 'stunning' tucatinib breast cancer data

Fierce Biotech

Wed, 12/11/19 - 10:27 am

Seattle Genetics

HER2+ breast cancer

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance

EP Vantage

Wed, 12/11/19 - 10:24 am

trastuzumab deruxtecan